There may be nearly two months left of 2019, but Novavax Inc. (NASDAQ: NVAX) is already counting down to 2020. The new year promises data from a late-stage clinical trial of seasonal flu vaccine NanoFlu, which the company hopes will prove to regulators, investors and the public what it has contended all along: that it will get the product — its first — to market. The company expects results from the vaccine candidate’s phase 3 study in the first quarter of 2020, Novavax CEO Stanley Erck…
from https://www.bizjournals.com/baltimore/news/2019/11/11/why-2020-could-be-a-make-or-break-year-for-novavax.html?ana=RSS&s=article_search
via https://baltimorecheckbook.tumblr.com/post/188996313527
No comments:
Post a Comment